Interventional News’ most popular stories last month included news of a US Food and Drug Administration pre-market approval submission of an ultrasound renal denervation system, as well as that of receipt of aforementioned approval for a drug-coated angioplasty balloon for peripheral artery disease; and a report of a British Society of Interventional Radiology presentation on the state of genicular artery embolization practice in the UK.
Otsuka Medical Devices and ReCor Medical have announced the filing of the pre-market approval application to the US Food and Drug Administration for the Paradise ultrasound renal denervation system in the treatment of uncontrolled hypertension.
The first trial participant has been treated as part of GENESIS II, a study of Embozene microspheres for genicular artery embolization as treatment of mild-to-moderate knee osteoarthritis.
The US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty catheter for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
The management of renal cancer patients featured prominently at this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (10–14 September, Barcelona, Spain), with discussions around patient selection and treatment planning preceding talks on the key therapeutic options in this space.
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI [chronic limb-threatening ischaemia] population,” and has a primary patency rate of 80% at 12 months in a per-protocol analysis population.
The British Society of Interventional Radiology (BSIR) annual scientific meeting (2–4 November, Glasgow, UK) featured a presentation on the existing body of evidence for GAE’s safety and efficacy and the roadmap for growing this further in order to gain UK National Institute of Health and Care Excellence (NICE) recommendation.
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (10–14 September, Barcelona, Spain) discussion participants underlined that while vying to make your voice heard at multidisciplinary team meetings is vital, this should not be motivated by ego, rather, by the common goal of what is best for the patient based on clinical effectiveness and patient outcome.
The National Institute for Health and Care Excellence (NICE)‘s new guidance states that microwave ablation can be used provided standard arrangements are in place for clinical governance, consent, and audit.
The Society of Interventional Radiology (SIR) published a position statement deeming endovascular thrombus removal “an acceptable treatment option in selected patients with acute iliofemoral deep vein thrombosis [DVT].”
The latest results from CLOUT and a propensity score-matched analysis of CLOUT versus ATTRACT bolster the evidence base for mechanical thrombectomy in the field of deep vein thrombosis (DVT) management.